Broad Institute

MARCH 14, 2024

Related groups Liu lab Choudhary lab Fischer lab Researchers studying the role of proteins in health and disease use experimental tools that inactivate proteins, destroy them, or prevent them from being made in cells. PACE allows researchers to rapidly evolve new proteins that have useful features.

Targeted Protein Degradation 141

Targeted Protein Degradation Small Molecule Medical Schools Science 141

The Pharma Data

JANUARY 5, 2021

Centers for Disease Control and Prevention. For the study, the researchers reviewed medical records of close to 119,000 kids, aged 4 to 17, who were treated at Texas Children’s Hospital in Houston more than once between 2011 and 2016. Of those, 1,164 had congenital heart disease. TUESDAY, Jan.

Disease 52

Disease Hospitals Doctors Treatment 52

Broad Institute

AUGUST 31, 2023

Related News Next generation prime editing systems move closer to possible therapeutic applications New CRISPR genome editing system offers a wide range of versatility in human cells Prime editing technologies allow scientists to precisely edit the genome in a variety of ways and could one day be used to treat genetic diseases.

DNA 145

DNA RNA Engineering Laboratories 145

New Drug Approvals

NOVEMBER 13, 2023

PATENT WO2023214314 VODOBATINIB FOR REDUCING PROGRESSION OF PARKINSON’S DISEASE (wipo.int) Vodobatinib (N’-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide), a c-Abl inhibitor is represented by Formula I (referred hereinafter interchangeably as vodobatinib or compound of Formula International Publication Nos.

Treatment 62

Treatment Disease Therapies Production 62

Drug Target Review

DECEMBER 1, 2023

The advancement could have great impact in making treatments using MSCs more accessible and efficient, for osteoarthritis, autoimmune and infectious diseases, and neurological disorders. Cell therapy In the field of cell therapy , cells are used as living drugs to tackle diseases or restore and replaced damaged cells.

Therapies 105

Therapies Engineering Treatment Disease 105

Drug Target Review

NOVEMBER 27, 2023

This approach is highly targeted, as STRIs selectively inhibit the translation of a specific network of disease-causing proteins without affecting the broader cellular machinery. By directly inhibiting the translation of disease-causing proteins, STRIs offer a novel strategy to overcome resistance mechanisms.

Molecular Biology 86

Molecular Biology Therapies Pharmaceuticals Treatment 86

Drug Hunter

AUGUST 21, 2023

Obtaining adequate drug exposure in the brain is key to treating CNS diseases effectively. Prodrugs Remain in “Proof-of-Concept” Stages Prodrug strategies for CNS deliver have also been applied with varying success , with the most famous example being L-Dopa for Parkinson’s disease. Figure 18.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206

The Pharma Data

JANUARY 12, 2021

Trends in albuminuria, reduced estimated glomerular filtration rate (eGFR), retinopathy, and self-reported cardiovascular disease were estimated. The researchers found a significant decrease in the prevalence of albuminuria from 1988-1994 to 2011-2018 (38.9 ” Abstract/Full Text (subscription or payment may be required).

Disease 52

Disease Research 52

Sygnature Discovery

OCTOBER 3, 2024

Since 2011, Sygnature Discovery has delivered over 40 novel pre-clinical and 25 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.

Science 52

Science Disease Marketing Production 52

The Pharma Data

NOVEMBER 17, 2020

31, 2011, to examine the impact of antibiotic exposure in the first two years of life. Zaira Aversa, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a population-based cohort study involving children born in Olmsted County, Minnesota, between Jan. 1, 2003, and Dec.

Therapies 52

Therapies Doctors Disease Research 52

Broad Institute

AUGUST 25, 2023

Thanks to the generous funding from Ted and Vada Stanley, and the collaborative environment of the Broad Institute, researchers at the Stanley Center have made strides toward understanding severe psychiatric disease with the goal of contributing to new understandings of pathogenesis, the identification of biomarkers, and above all, new treatments.

Research 52

Research DNA International Disease 52

NIH Director's Blog: Drug Development

FEBRUARY 4, 2014

Recent advances in genomics, proteomics, imaging, and other technologies have led to the discovery of more than a thousand risk factors for common diseases—biological changes that ought to hold promise as targets for drugs. These three-to-five year pilot projects will set the stage for broadening AMP to other diseases and conditions.

Drug Development 52

Drug Development Disease Drugs Pharmaceuticals 52

The Pharma Data

DECEMBER 3, 2020

The researchers examined the association between ACO alignment and the primary outcome of total spending for beneficiaries on long-term dialysis from prior to ACO implementation (2009 to 2011) through implementation of the Comprehensive End-Stage Renal Disease Care model in 2015.

Research 52

Research Disease 52

The Pharma Data

NOVEMBER 2, 2020

The analysis included 3,000 participants with 24-hour ambulatory BP monitoring (ABPM) and 17,969 participants in the 2011-2016 National Health and Nutrition Examination Survey without ABPM. percent), or chronic kidney disease (21.5 The researchers found that the estimated prevalence of masked asleep hypertension among U.S. percent (44.4

Pharmaceuticals 52

Pharmaceuticals Treatment Disease Research 52

Sygnature Discovery

OCTOBER 9, 2024

Since 2011, Sygnature Discovery has delivered over 40 novel pre-clinical and 25 clinical compounds, with its scientists named on over 170 patents. Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more.

Science 52

Science Disease Research Pharmaceuticals 52

The Pharma Data

NOVEMBER 30, 2020

It’s a simple concept: After a health care provider explains various details on treatment plans, medications and how to manage the disease at home, they then ask the patient to repeat back the information. Data came from the 2011-2016 Medical Expenditure Panel Survey administered by the U.S. Another 88 million have prediabetes.

Doctors 52

Doctors Medical Schools Hospitals Disease 52

The Pharma Data

NOVEMBER 1, 2020

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Clinical Pharmacology 52

Clinical Pharmacology Small Molecule Clinical Research Science 52

NIH Director's Blog: Drug Development

SEPTEMBER 20, 2018

While researchers had solved the structure of a GPCR bound to another class of G proteins, known as stimulatory G proteins (G s ) in 2011[3], the image you see above represents the first such glimpse of a GPCR bound to any G i protein. 2011 Jul 19;477(7366):549-55.

Laboratories 52

Laboratories Research Regulations Drugs 52

The Pharma Data

JANUARY 14, 2021

Xalkori is a tyrosine kinase inhibitor indicated since 2011 for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK- or ROS1-positive. In the 23 patients who achieved a response, 39% maintained that response for at least six months, and 22% maintained it for at least a year. Most Read Today. Source link.

FDA Approval 52

FDA Approval FDA Therapies Treatment 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration (FDA) has approved Benlysta to treat lupus nephritis (lupus-related kidney disease) in adults. The decision makes Benlysta the first lupus therapy authorized to treat this potentially life-threatening complication of the disease. The FDA first approved Benlysta for lupus in 2011.

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52

New Drug Approvals

JANUARY 31, 2024

In the CPRC stage, disease is characterized by high AR expression, AR amplification and persistent activation of the AR signalling axis by residual tissue/tumor androgens and by other steroid hormones and intermediates of steroid biosynthesis. 71(20), 6503-6513, 2011). 7 H 8 O 3 S Molecular Weight 590.71 et al, Cancer Res.,

Therapies 52

Therapies Disease Treatment Production 52

The Pharma Data

APRIL 27, 2023

“Obstructive hypertrophic cardiomyopathy can be a debilitating and life-changing heart disease, reducing physical functioning and overall well-being, and often runs in families. Senior Vice President, Cardiovascular Development at Bristol Myers Squibb.

Therapies 40

Therapies Treatment Trials Disease 40

Sygnature Discovery

JULY 31, 2023

Founded in 2011, NuChem Sciences delivers expert integrated and standalone discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology.

Computational Chemistry 52

Computational Chemistry Science Clinical Trials Pharmaceutical Companies 52

Creative Biolabs

JUNE 20, 2022

Food and Drug Administration (FDA) in 2011. Dr. Fu noted that the method they described could also be used to identify neoPPI targets caused by mutations critical to other human diseases. Subsequently, the authors found that BRAF-mutated cancer cells were more sensitive to the compound DNQ (deoxynyboquinone).

Therapies 52

Therapies Regulations FDA Drugs 52

FDA Law Blog: Drug Discovery

FEBRUARY 28, 2024

This is the third withdrawal of an accelerated approval FDA has performed, following Avastin in 2011 and Makena in 2023. In contrast , the two previous withdrawals, Makena in 2023 and Avastin in 2011, took 30 months and 11 months, respectively.

FDA 59

FDA Trials Therapies Drugs 59

The Pharma Data

AUGUST 9, 2020

Pivotal phase III stud y of etrolizumab in Crohn’s disease is ongoing. Roche is studying additional investigational medicines in inflammatory bowel diseases. We are fully analysing these data to learn more about how we might address the needs of people with this devastating disease.

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

NIH Director's Blog: Drug Development

MARCH 11, 2014

But this approach doesn’t just provide predictions of risk; it may also provide a path to developing new ways of treating and preventing this serious, chronic disease that affects about 26 million Americans. Over time, this leads to heart disease, stroke, blindness, nerve damage, kidney damage, and amputations. Nat Rev Drug Discov.

DNA 52

DNA Drugs Disease Research Laboratories 52

FDA Law Blog: Drug Discovery

JANUARY 4, 2023

The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023. The Agency referred to its 2011 FDA Guidance for Industry: Potency Tests for Cellular and Gene Therapy Products during the town hall. Comparability.

Therapies 59

Therapies Engineering Production FDA 59

The Pharma Data

JANUARY 24, 2021

Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board. His research focuses on the role of the microbiome in immune defense and disease resistance. “We About Diversigen Inc.

Research 40

Research Bioinformatics Laboratories International 40

The Pharma Data

JANUARY 20, 2021

21, 2021 /PRNewswire/ — Dynacure , a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced today the appointment of Jean M. STRASBOURG, France and PHILADELPHIA , Jan. Franchi to its Board of Directors.

Treatment 40

Treatment Pharmaceuticals Drug Development Science 40

LifeSciVC

DECEMBER 13, 2022

In the spring of 2011, we came out of stealth with a blog “ Discovering Nimbus ”, which highlighted the three key elements of the “experiment”: a cutting edge in silico discovery engine, with a truly virtual and globally distributed operating model, and a unique asset-centric LLC-based corporate structure (also described here ).

Clinical Trials 40

Clinical Trials Trials Engineering Disease 40

The Pharma Data

NOVEMBER 10, 2020

Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018 , Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Creative Biolabs

JUNE 29, 2023

According to statistics, 103 GPCRs currently have clinically used drugs for various diseases. GPCR is the most valuable target for drug development, and more drugs will be used to treat various diseases in the future. And among the drugs currently under development, there are 142 compounds targeting 83 different GPCRs.

Therapies 52

Therapies Small Molecule Drugs Drug Development 52

Broad Institute

JANUARY 14, 2025

By Allessandra DiCorato January 14, 2025 Credit: Maria Nemchuk, Broad Communications Eric Minikel and Sonia Vallabh run a lab with a singular focus: preventing and treating prion disease within their lifetime. When I received my genetic test report in 2011, the world had never heard of base editing.

Disease 144

Disease DNA Protein Production Treatment 144

New Drug Approvals

AUGUST 21, 2023

At Roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease (COPD). [7] April 2011). Kaplan FS, Shore EM (April 2011). 22] Ipsen acquired Clementia in 2019. [23] 23] SYN Desjardins, C., Grogan, D. . 17 (4): 454–60. doi : 10.1038/nm.2334.

FDA 52

FDA Clinical Trials Treatment Pharmaceuticals 52

Drug Target Review

JUNE 19, 2024

There are many opportunities to address conditions of the eye, such as retinitis pigmentosa, dry age-related macular degeneration or any of the hundreds of inherited retinal diseases. MSTX), from 2010, and was also a member of its board of directors from 2011, until Mast’s merger with Savara, Inc. SVRA) in April 2017.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Agency IQ

APRIL 12, 2024

Draft guidance on potency assays for CGT products garners extensive stakeholder input Late last year, the FDA published a draft update to its 2011 guidance on potency assays for cell and gene therapy products, unveiling a major shift in approach to the issue. As a result, the 2011 guidance was generally seen as basic and outdated.

Production 40

Production FDA Therapies Biochemical Assays 40